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Malaria remains a major public health problem particularly in sub Saharan Africa in which majority of the 
populations are at  risk1. Late diagnosis and treatment of the disease can lead to life threatening  conditions2. The 
World Health Organization (WHO) implements vector control, early diagnosis and prompt treatment strategies 
to eliminate  malaria3. Accordingly, the early, rapid and accurate diagnosis is an essential component in malaria 
control and elimination programs. Microscopic detection of malaria parasites is still considered the gold standard 
for diagnosis of the disease; this method is relatively sensitive and allows parasitic quantitatification and species 
 identification4,5. However, in remote areas, this procedure may not be easily available due to the requirement 
of high-quality equipment and the challenge in maintaining well-trained  microscopists6. Alternatively, WHO 
recommends the use of rapid diagnostic tests (RDTs), which have later become an alternative way of establishing 
the rapid diagnosis of malaria  infections7. Accordingly, RDTs were implemented as part of malaria case manage-
ment along with microscopy for diagnosing malaria among suspected cases in  Sudan8.
Most of the current malaria RDTs target the histidine-rich protein-2 (HRP2), which is a species-specific 
antigen of Plasmodium falciparum9. Recent reports indicate that PfHRP2-based RDTs may provide false nega-
tive  results10. Though among the causes of false negative results are product quality, transportation, storage 
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distribution, parasite density and due to the existence of P. falciparum isolates that lack the pfhrp2 gene. Such 
deletions have been reported in a broader range of malaria-endemic countries in  Africa11–13, South  America14,15 
and  Asia16.
Recent evidence suggested that P. falciparum isolates with pfhrp2 gene deletion also circulate in the neighbour-
ing  countries17,18 with more than 80% of microscopically confirmed isolates found to carry pfhrp2 gene deletion 
in  Eritrea19. Recently, P. falciparum isolates with deleted pfhrp2 was also reported in UK travellers from Sudan 
and south  Sudan11. This condition highlights the importance of molecular surveillance to detect these deletions 
because they could lead to false-negative diagnoses when using PfHRP2-based malaria  RDTs20.
Despite the diagnostic threat posed by P. falciparum parasites lacking the pfhrp2 gene, sporadic data is avail-
able about the existence of P. falciparum parasites with pfhrp2 deletion in Sudan, which has high burden of 
malaria in the region. Screening of P. falciparum parasites with pfhrp2 deletions in Sudan is essential to asses RDTs 
performance and the impact on clinical case management and malaria elimination efforts. Therefore, the present 
study aimed to investigate the pfhrp2 gene deletion in P. falciparum isolates in Nayala City, Western Sudan.
Results
A total of 300 suspected patients with malaria were screened for malaria parasite by microscopy; 113 patients 
were positive for P. falciparum infection. Subsequently, the microscopically confirmed specimens were tested 
against HRP2-based malaria RDTs. Amongst the isolates, the PfHRP2 RDTs identified 106 (93.81%) positives. 
A total of 7 out of 113 of P. falciparum microscopy-confirmed cases were RDT negative. This finding resulted 
in overall 93.81% [95% confidence interval (CI) 87.65–97.47] and 100% (95% CI 98.05–100) sensitivities and 
specificities of the PfHRP2-based RDTs respectively (Table 1). The parasite density of the seven RDT-negative 
specimens was 96–5,120 asexual parasites/µl with a mean of 1,540 parasites/µl.
Confirmation of P. falciparum infection by pcR. All the microscopy-confirmed P. falciparum cases 
were P. falciparum infections (113 out of 113) because all of them generated PCR products for P. falciparum 
specific ssrRNA primers. Therefore, the 106 RDT-positive isolates were found not eligible for further pfhrp2 
deletion analysis. The remaining seven isolates were further investigated to examine whether pfhrp2 gene was 
lacking given the negative RDT results of these specimens.
Detection of Pfhrp2 gene.  Plasmodium falciparum ssrRNA gene was amplified in all seven RDT-negative 
isolates. The samples were subjected to another round of PCR to amplify the flanking regions of pfhrp2. The 
pfhrp2 gene was successfully amplified in most of the isolates (six out of seven, 85.7%), this exclude the dele-
tion of the entire gene in all these samples. Amongst the seven samples, the entire pfhrp2 gene was deleted in 
one sample (14.3%). The pfcsp gene was successfully amplified to confirm this deletion. In addition the parasitic 
density of this sample was relatively high (Table 2). 
Table 1.  RDT performance for the diagnosis of malaria compared to microscopy as the gold standard.
RDTs
Positive, n (%) Negative, n (%) Total
Microsopy
Positive, n (%) 106 (100) 7 (3.6) 113
Negative, n (%) 0 (0) 187 (96.4) 187
Total 106 194 300
Table 2.  Diagnostic profile and parasite density of the RDT-negative/microscopy positive isolates.
Sample ID
Results
RDTs Microscopy nPCR HRP2 Parasiteamia (p/μl)
1 − + + + 5,120
2 − + + + 2,112
93 − + + + 176
203 − + + − 1,744
207 − + + + 96
230 − + + + 368
283 − + + + 1,168
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Discussion
Despite the substantial drop in malaria cases and deaths over the past decade, efforts should be intensified to 
ensure prompt and sensitive diagnosis and effective treatment. PfHRP2-based RDTs are valuable tools for P. 
falciparum malaria diagnosis, especially in areas where routine microscopic diagnosis is inaccessible. However, 
studies across the globe have reported the reduced diagnostic performance of PfHRP2-based RDTs. Evidence 
from many African countries revealed that HRP2-based RDTs failed to detect P. falciparum  parasites19. This 
observed failure is attributed to various factors, including the lack of the pfhrp2 gene, which is an important fac-
tor responsible for false negative results. In Sudan, there were a few reports of false negative RDT results associ-
ated with pfhrp2-negative, though the availability of data regarding the Pfhrp2 deletion in Sudanese population 
are  limited21. Given that pfhrp2-deleted P. falciparum isolates have been reported in the  country11,22, this study 
investigated the possible circulation of parasites with pfhrp2 deletions in western part of Sudan.
Our study reports, for the first time, the presence of P. falciparum parasites with pfhrp2 deletion in western 
Sudan. Of the 7 false negative RDT results, one isolate was smear-positive and pfhrp2 PCR-negative. The pres-
ence of parasite DNA and its quality was verified by two other independent genes, suggesting that the sample has 
pfhrp2 gene deletion. While the cause of false negative RDT for the 6 samples (5.3%) is unknown, 0.9% (1/113) 
of the false negative can be explained by pfhrp2 deletion. The six samples determined as positive by microscopy 
and negative using HRP2 RDT were confirmed positive by PCR as indicated by the amplified pfhrp2 gene. This 
finding could be attributed to the sequence variability among the pfhrp2 region or low parasitaemia as some of 
the samples had parasitaemia below the detection limit of  RDT12,23. Among the false negative isolates by RDT, 
the number of parasites density varies from 96 to 5,120 asexual parasites/µl. A very low parasite densities or 
target antigen concentrations could also contributed to false negative results. Another possible explanation is 
that other factors, including the product quality, transportation, storage and distribution, possibly affected the 
performance of RDTs. This is very unlikely as SD Bioline Pf/Pv/Mixed Combo cassettes used in this study was 
prequalified by WHO, and the shipment and storage conditions in the field were optimal and followed WHO 
recommendations. Thus, they are less likely to be the reasons for false negative results in this study. The most 
likely explanation could be low parasitaemia and/or sequence variation of the repeat region of the pfhrp2, which 
is targeted by the HRP2-based RDT.
The only one pfhrp2 negative isolate may not reflect the actual number of the pfhrp2 negative P. falciparum 
among the study population. This is because the 106 RDT positive isolates were not screened for pfhrp2 gene 
deletion. The RDT positive signal could be generated from HRP3 due to the cross reactivity of HRP3 antigen with 
the HRP2. In this context, the actual number of pfhrp2 deletion could be higher than the estimated prevalence. 
Nevertheless, whether the deletion of pfhrp2 is compensated by the presence of HRP3 could not be determined 
and this is one of the limitations of the study.
Limited information is available regarding the deletions of pfhrp2 gene in samples obtained from Sudanese 
patients. A similar recent study with a small sample size conducted by our group in the centre of Sudan reported 
genetic variations in pfhrp2 and pfhrp2-negative samples but deletion was not  confirmed21. Our current study, 
however, found one deletion that caused RDT negative result. Study area, sample size and collection period 
could explain the differences in findings. Other studies also reported genetic variation and suspected deletion 
of pfhrp2  gene22 as well as pfhrp2 deletions in malaria patients among UK travellers from  Sudan11, though it is 
not clear which part of Sudan the UK patient travelled from.
To date, parasites lacking the pfhrp2 gene have been unequivocally identified in many malaria endemic 
 regions16. Despite the low prevalence of pfhrp2 deletion in the current study, the rates of deletions vary consid-
erably in Africa and globally. Remarkably high rates of pfhrp2 gene deletions were reported from neighbouring 
 Eritrea17. Moreover, findings from several countries indicated that P. falciparum isolate with pfhrp2 gene dele-
tion is circulating in east Africa, including  Kenya18, Tanzania and  Uganda24, South  Sudan11 and  Rwanda25. By 
contrast, reports of presence of pfhrp2 gene deletions in West Africa have been limited, including in  Mali12 and 
 Senegal13. Recent studies provide evidence of deletion of the pfhrp2 gene as reported from Equatorial  Guinea26 
and  Nigeria27. However, in many highly malaria-endemic countries, data about pfhrp2 deletion are missing. This 
underscores the importance of conducting comprehensive molecular surveillance to investigate the pfhrp2 gene 
deletion in all endemic countries.
The study was not designed to systematically identify pfhrp2 deletion in western Sudan and the prevalence 
does not reflect the true prevalence in the whole region. However, the prevalence of pfhrp2 deletion is consider-
ably lower than 5%, which is the minimum threshold needed to change the RDT types based on WHO guidelines. 
Evidently, malaria RDTs tests that rely on PfHRP2 for the detection of P. falciparum infections are still suitable 
for P. falciparum malaria diagnosis in Sudan.
Despite the importance of monitoring the deletion of pfhrp2 gene across the whole country, this study was 
limited by the collection of samples from a single location in the western part of Sudan. The research needs to be 
expanded to cover other geographic regions given that this finding may not be representative of the situation in 
the whole country. Moreover, screening of pfhrp2 gene as well as the pfhrp3 gene among RDTs positive isolates 
could help in determining the actual number of HRP gene deletion among the study population, which is one 
of the limitations of the current study.
In conclusion, this study revealed that P. falciparum isolates with pfhrp2 gene deletion are present in the 
parasite populations in western Sudan. The PfHRP2-based RDTs used in this study detected the majority of P. 
falciparum infections. Further studies, including a large and systematic collection from different geographical 




Scientific RepoRtS |        (2020) 10:12822  | https://doi.org/10.1038/s41598-020-69756-8
www.nature.com/scientificreports/
Methods
Study population and site. A total of 300 suspected patients with malaria from 4 health centres in Nyala 
City were enrolled in a cross-sectional study conducted between July 2018 and April 2019. Nyala is the capital 
of the South Darfur State, Western Sudan and covers an area of about 127,300 km2. The city lies in a savannah 
zone between 9° 30′ 13″ N latitude and 15° 27′ 28″ E longitude. Patients presented with symptoms consistent 
with uncomplicated malaria attending the selected health centres were enrolled and blood smears for Malaria 
were obtained from each patient.
Sample collection. A total of 300 venous blood samples (3 ml each) were collected from each participant 
for the preparation of thin and thick blood films and for rapid diagnostic tests (RDTs) and for DNA extraction. 
An aliquot of blood was saved on a Whatman 3MM filter paper (Whatman, Clifton, NJ, USA) for parasite speci-
men preservation.
Microscopy and RDt analyses. Thick and thin blood smears were prepared and stained with 10% Giemsa 
for 15 min. Subsequently, the stained slides were examined under a 100 × oil immersion microscope by two inde-
pendent expert microscopists (conducted by a senior laboratory technician in malaria reference laboratory in 
the state ministry of health). Parasitaemia was calculated by counting the number of parasites observed per 200 
leukocytes and assuming a total of 8,000 leukocytes/µl. Simultaneously, all blood samples were assayed with SD 
BIOLINE Malaria Ag P.f/P.v RDT, which is a qualitative and differential test for the immunological detection of 
HRP2 and parasite lactate dehydrogenase of P. falciparum and P. vivax, respectively. The RDT assays were per-
formed, and the results were interpreted according to the instructions provided by the manufacturers.
DNA  extraction.  For molecular analysis, genomic DNA was extracted from blood samples by using a 
Geneius™ Micro gDNA Extraction kit (Geneaid Biotech Ltd., Taiwan) in accordance with the manufacturer’s 
instructions. DNA was resuspended in 100 µl elution buffer and stored at − 20 °C.
Confirmation of P. falciparum infection by polymerase chain reaction (PCR).  The presence of P. 
falciparum infection was further confirmed by species-specific nested PCR by using a small subunit ribosomal 
RNA (ssrRNA) gene via a previously described two-step  procedure28. Plasmodium-specific primers were first 
used, and the PCR product of the positive samples was used as a template in a multiplex PCR system through 
species-specific primers.
Detection of pfhrp2 gene.  Microscopic and PCR positive P. falciparum samples but RDT negative were 
subjected to pfhrp2 PCR amplification. Specific primers Pfhrp2-F (5′ ATT CCG CAT TTA ATA ATA ACTTG TGT 
AGC 3′) and Pfhrp2-R (5′ ATG GCG TAG GCA ATG TGT GG 3′) targets exon 2 of pfhrp2 were used as described 
 previously12.
The PCR mixture had a total volume of 20 µl containing 4 µl of 5 × HOT FIREPol Blend Master Mix, 0.75 µM 
each primer and 2 µl DNA. The thermoprofile process consisted of an initial denaturation step at 95 °C for 4 min, 
followed by 35 cycles at 95 °C for 30 s, 58 °C for 45 s, 72 °C for 1 min and a final extension step at 72 °C for 5 min. 
Furthermore, the samples in which no pfhrp2 was amplified were subjected to P. falciparum circumsporozoite 
gene (pfcsp) PCR amplification, with the assumption that successful ssrRNA and csp gene amplification indicates 
reasonable quantity and quality of DNA that would allow pfhrp2 amplification. Thus, all the samples that were 
not amplified by pfhrp2 PCR may have pfhrp2 gene deletion.
ethical statement. This study protocol was reviewed and approved by the Institute of Molecular Biology, 
University of Nyala and the committee of the Research directorate, Federal Ministry of Health (fmoh/nhrc/rd/
rec). Prior to blood samples collection, written informed consent was obtained from all subjects and also from 
a parent or guardian for children less than 18 years of age. All methods were performed in accordance with the 
relevant guidelines and regulations.
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